Crucial Considerations in Monitoring Process Performance and Product Quality - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Crucial Considerations in Monitoring Process Performance and Product Quality
The author outlines key considerations for carrying out a structured approach to monitoring process performance and ensuring product quality.

Pharmaceutical Technology
Volume 34, pp. S38-S42

Figure 3: Control chart showing batch tablet weight produced using two presses (A and B). UCL is upper control limit and LCL is lower control limit.
Figure 3 shows a control chart for a total weight of 10 tablets manufactured by two tablet presses. The graphic demonstrates that both presses are stable and in control and producing tablets with the same average weight and variation.

Figure 4: Control chart showing assay values of batches produced over three years. UCL is upper control limit and LCL is lower control limit.
Figure 4 shows a control chart for assay values for batches produced over a 3-year period. The process is stable through the middle of Year 2 and begins to decrease in Year 3. When a process adjustment is made, the batch assay values return close to the values observed in Year 1. This example is interesting because a process shift is shown, but none of the batch assay values are close to the assay specifications of 90–110%.

Out-of-specification (OOS) and out-of-control (OOC) values require investigation. These values are not always caused by manufacturing problems, and may be caused by sampling errors, testing errors, or human administration errors such as recording or data keying. The causes of OOS and OOC measurements should be carefully considered when interpreting the OOC and OOS values and deciding on appropriate action.

Process-capability analysis. A process-capability analysis is conducted to determine the ability of the process to meet product specifications. The Ppk value represents the ratio of the difference between the process average and the nearest specification divided by three times the process SD (see Equation 2).

Table I: Summary of process performance index (Ppk value) interpretation.
Where A is the upper specification minus the process average and B is the process average minus the lower specification. Two main statistics are used to measure process capability: percent of the measurements OOS and the process Ppk value. The interpretation of the Ppk value is summarized in Table I.

Figure 5: Process capability for a tablet weight of Ppk = 1.91. LSL is lower specification limit and USL is upper specification limit.
Process capability indices of Ppk of 2.0 and higher are consistent with high-performance processes or robust processes. Figure 4 shows an example of process capability for tablet weight. In this case, the Ppk value is 1.91 (an excellent category) which is based on the distribution of tablet weights being a considerable distance from the lower and upper specifications for tablet weight.

When a process is robust, small process upsets will not create OOS product. Accordingly, small OOC signals do not result in OSS product. A process is said to be "robust" if its performance is not significantly uninfluenced by variations in process inputs (e.g., raw material lot), process variables (e.g., press force and speed), and environmental variables (e.g., ambient temperature and humidity).

Figure 6: Boxplots showing tablet hardness for two tablet presses (X and Y).
Variance analysis. Another way to assess process stability is to study the variation in process performance that is caused by potential special-cause variation (e.g., tablet presses, raw-material lots, process operating teams). Analysis of variance (ANOVA) enables one to identify variables that can increase variation in tablet parameters and that may produce OOS product (see Figure 6).

The boxplot in Figure 6 shows the distribution of tablet hardness values for a batch of tablets produced by two different tablet presses (X and Y). Press X has a wider hardness distribution than Press Y, yet none of the hardness values are outside the hardness specification of 1–6 kp. With this data in mind, the process operators can determine whether to make process adjustments.

After statistical significance of a comparison (e.g., average of Tablet Press X versus average of Tablet Press Y) is established, the practical significance of the difference in average values must be considered. This assessment is frequently carried out by expressing the observed difference in average values as a percentage of the overall process average. Subject-matter expertise is used to evaluate the practical importance of the observed percent difference.

Nested analysis of variance is another form of ANOVA used to assess process stability. Nested ANOVA can estimate the portion of the total variation in the data attributed to various sources of variation. Typically, the larger the percent of the total variation attributed to a source of variation, the more important is the source of variation. Low amounts (< 30%) of long-term variation as determined by a nested ANOVA indicate a stable process.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here